Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | June 23, 2026 | June 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2036-06-23 | Direct | 32,000 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 32,000 · Balance 32,000 F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Deciphera Pharmaceuticals, Inc.
Report date June 11, 2024 · Filed June 12, 2024
Section 16 reporting ended · disclosed 2024-06-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Disposition to issuer · Disposed 35,233 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.13 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-11 · Disposition to issuer · Disposed 7,181 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.05 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-11 · Disposition to issuer · Disposed 12,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.98 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-11 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.91 | Direct | 0 |
Reported balance
After 2024-06-11 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-06-11 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration.
Renovacor, Inc.
Report date December 01, 2022 · Filed December 06, 2022
Section 16 reporting ended · disclosed 2022-12-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-12-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-12-01 · Grant · Acquired 3,586 · Balance 3,586 F1: Represents shares of common stock underlying restricted stock units granted pursuant to that certain Agreement and Plan of Merger, dated as of March 22, 2021, by and among the Issuer, Renovacor Holdings, Inc. and CHAQ 2 Merger Sub, Inc. (the "SPAC Merger Agreement") as Earnout RSU Awards (as defined in the SPAC Merger Agreement). Pursuant to the terms of the SPAC Merger Agreement, the Earnout RSU Awards have fully vested upon the consummation of the merger contemplated by the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement"). Row 2 · 2022-12-01 · Disposition to issuer · Disposed 3,586 · Balance 0 F2: The shares underlying the Earnout RSU Awards were cancelled and converted into the right to receive the Per Share Merger Consideration (as defined in the Merger Agreement). |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2030-01-28 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-12-01 · Disposition to issuer · Disposed 9,060 · Balance 0 F3: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F4: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2031-09-03 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-12-01 · Disposition to issuer · Disposed 24,000 · Balance 0 F3: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F4: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
| Stock OptionSEC Table II · derivative / convertible security · Expires 2032-05-25 | Direct | 0 |
Reported balance
After 2022-12-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-12-01 · Disposition to issuer · Disposed 12,000 · Balance 0 F3: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F4: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying restricted stock units granted pursuant to that certain Agreement and Plan of Merger, dated as of March 22, 2021, by and among the Issuer, Renovacor Holdings, Inc. and CHAQ 2 Merger Sub, Inc. (the "SPAC Merger Agreement") as Earnout RSU Awards (as defined in the SPAC Merger Agreement). Pursuant to the terms of the SPAC Merger Agreement, the Earnout RSU Awards have fully vested upon the consummation of the merger contemplated by the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement").
F2: The shares underlying the Earnout RSU Awards were cancelled and converted into the right to receive the Per Share Merger Consideration (as defined in the Merger Agreement).
F3: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent.
F4: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement.
Xenetic Biosciences, Inc.
Report date August 09, 2017 · Filed August 23, 2017
Section 16 reporting ended · disclosed 2017-08-23. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 23, 2026 Filed Jun 24, 2026 20:32 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001691160-26-000002 · ownership.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 32,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 23, 2027 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 12:38 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0000950170-25-087708 · ownership.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2035-06-17 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 17, 2026 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 26, 2024 Filed Jun 27, 2024 12:34 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $5.71 | $0.00 |
DisclosureSEC source: 0000950170-24-078168 · ownership.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2034-06-26 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 26, 2025 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:30 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $14.91 | Not disclosed |
DisclosureSEC source: 0000950170-24-072195 · ownership.xml · derivative · entry 5 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:30 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,500 | Not disclosed Strike: $13.98 | Not disclosed |
DisclosureSEC source: 0000950170-24-072195 · ownership.xml · derivative · entry 4 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,500 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:30 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,000 | Not disclosed Strike: $21.05 | Not disclosed |
DisclosureSEC source: 0000950170-24-072195 · ownership.xml · derivative · entry 3 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:30 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,181 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0000950170-24-072195 · ownership.xml · derivative · entry 2 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,181 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 00:30 UTC | Deciphera Pharmaceuticals, Inc. NA · Entity 90033 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,233 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0000950170-24-072195 · ownership.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,233 shares Expires not disclosed F1 · kind: This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. ("Parent"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share for a price per share of $25.60, without interest and subject to tax withholding (the "Merger Consideration"). Effective as of June 11, 2024 (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. F2 · price: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration. Read SEC document |
| June 28, 2023 Filed Jun 29, 2023 13:00 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001209191-23-040133 · doc4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2033-06-28 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) June 28, 2024 or (ii) the date of the next Annual Meeting of Stockholders of the Issuer; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors (the "Board") of the Issuer or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 20:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $14.91 | $0.00 |
DisclosureSEC source: 0001209191-23-039327 · doc4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-06-20 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 21, 2024, subject to continued service through such date. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:22 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023384 · form4.xml · derivative · entry 5 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2032-05-25 F3 · derivative.exercise_price: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F4 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:22 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 24,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023384 · form4.xml · derivative · entry 4 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2031-09-03 F3 · derivative.exercise_price: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F4 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:22 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerStock Option · Derivative | 9,060 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-023384 · form4.xml · derivative · entry 3 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,060 shares Expires 2030-01-28 F3 · derivative.exercise_price: Represents Company Options (as defined in the Merger Agreement), whether vested or unvested, that were assumed by Rocket in the merger and replaced with an option to purchase a number of Rocket common stock equal to the product of (A) the number of Issuer shares subject to such Company Option as of immediately prior to the First Effective Time (as defined in the Merger Agreement), multiplied by (B) the Exchange Ratio, rounded down to the nearest whole number of Rocket common stock, at an exercise price per Rocket common stock underlying such option equal to the quotient obtained by dividing (x) the per share exercise price of Company Options immediately prior to the First Effective Time by (y) the Exchange Ratio, rounded up to the nearest whole cent. F4 · derivative.exercise_date: Each Company Option described herein shall be subject to the same terms and conditions as applied to the corresponding Company Option as of immediately prior to the First Effective Time, except as otherwise provided in the Merger Agreement. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:22 UTC | Renovacor, Inc. RCOR · Entity 114644 | Disposition to issuerCommon Stock | 3,586 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023384 · form4.xml · nonDerivative · entry 2 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: The shares underlying the Earnout RSU Awards were cancelled and converted into the right to receive the Per Share Merger Consideration (as defined in the Merger Agreement). Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 02:22 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantCommon Stock | 3,586 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-22-023384 · form4.xml · nonDerivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,586 F1 · price: Represents shares of common stock underlying restricted stock units granted pursuant to that certain Agreement and Plan of Merger, dated as of March 22, 2021, by and among the Issuer, Renovacor Holdings, Inc. and CHAQ 2 Merger Sub, Inc. (the "SPAC Merger Agreement") as Earnout RSU Awards (as defined in the SPAC Merger Agreement). Pursuant to the terms of the SPAC Merger Agreement, the Earnout RSU Awards have fully vested upon the consummation of the merger contemplated by the Agreement and Plan of Merger, dated as of September 19, 2022, by and among the Issuer, Rocket Pharmaceuticals, Inc. ("Rocket") and the other parties thereto (the "Merger Agreement"). Read SEC document |
| October 13, 2022 Filed Oct 17, 2022 20:36 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 14,240 | $0.00 Strike: $2.81 | $0.00 |
DisclosureSEC source: 0001209191-22-053829 · doc4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,240 Underlying: Common Stock · 14,240 shares Expires 2032-10-13 F1 · derivative.exercise_date: This option is subject to time-based vesting. The shares underlying this option shall vest and become exercisable upon the earlier of (i) October 13, 2023 or (ii) the date of the next Annual Meeting of Stockholders of the Company; provided, however, that all vesting shall cease if the Reporting Person resigns from the Board of Directors of the Company or otherwise ceases to serve as a Director, unless the Board determines that the circumstances warrant continuation of vesting. Read SEC document |
| June 23, 2022 Filed Jun 24, 2022 20:05 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 18,500 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-22-039197 · doc4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,500 Underlying: Common Stock · 18,500 shares Expires 2032-06-22 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 23, 2023, subject to continued service through such date. Read SEC document |
| May 25, 2022 Filed May 27, 2022 20:04 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantStock Option · Derivative | 12,000 | $0.00 Strike: $1.94 | $0.00 |
DisclosureSEC source: 0001062993-22-013695 · form4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-05-25 F1 · derivative.exercise_date: The option vests on the earlier of (a) May 25, 2023, or (b) the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 23:02 UTC | Renovacor, Inc. RCOR · Entity 114644 | GrantOption · Derivative | 24,000 | $0.00 Strike: $7.73 | $0.00 |
DisclosureSEC source: 0001192482-21-000714 · edgar.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-09-03 F1 · derivative.exercise_date: The stock options will vest and become exercisable 25% on the first anniversary of the grant and the remainder will vest and become exercisable in 36 equal monthly installments on the 3rd of each month for the remaining 36 months, subject to the Reporting Person's continuous service as of each such date. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 20:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $35.86 | $0.00 |
DisclosureSEC source: 0001209191-21-043268 · doc4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-06-22 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 23, 2022, subject to continued service through such date. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 20:00 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $56.46 | $0.00 |
DisclosureSEC source: 0001209191-20-036231 · doc4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 10, 2021, subject to continued service through such date. Read SEC document |
| June 11, 2019 Filed Jun 13, 2019 20:10 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $21.05 | $0.00 |
DisclosureSEC source: 0001209191-19-036738 · doc4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in full on June 11, 2020, subject to continued service through such date. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:23 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $25.73 | $0.00 |
DisclosureSEC source: 0000899243-18-013547 · doc4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan and will vest in full on May 17, 2019, subject to the Reporting Person's continuous service with the Issuer. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 20:36 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,181 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0000899243-17-023131 · doc4.xml · derivative · entry 4 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,181 Underlying: Common Stock · 7,181 shares Expires 2027-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through such dates. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 20:36 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,271 | Not disclosed Strike: $6.13 | Not disclosed |
DisclosureSEC source: 0000899243-17-023131 · doc4.xml · derivative · entry 3 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,181 shares Expires 2027-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F4 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of May 26, 2017, subject to continued service through such dates. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 20:36 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 35,233 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0000899243-17-023131 · doc4.xml · derivative · entry 2 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,233 Underlying: Common Stock · 35,233 shares Expires 2026-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the total number of options to purchase common stock of the Issuer received upon the exchange of options to purchase common stock of Deciphera Pharmaceuticals, Inc. for options to purchase common stock of the Issuer pursuant to the Merger Agreement. F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F2 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 27, 2016, subject to continued service through such dates. Read SEC document |
| October 02, 2017 Filed Oct 2, 2017 20:36 UTC | Deciphera Pharmaceuticals, Inc. DCPH · Entity 90033 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,236 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0000899243-17-023131 · doc4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,233 shares Expires 2026-09-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F1 · price: Immediately prior to the closing of the Issuer's initial public offering, these options to purchase common stock of Deciphera Pharmaceuticals, LLC were exchanged for options to purchase common stock of the Issuer on a 1 for 5.65 basis pursuant to that certain Reorganization Agreement and Plan of Merger by and among the Issuer, Deciphera Pharmaceuticals, LLC and the other parties named therein, dated September 26, 2017 (the "Merger Agreement"). These transactions were exempt from Section 16(b) in reliance upon Rule 16b-3 and Rule 16b-6(b). F2 · derivative.exercise_date: This stock option award was issued pursuant to Deciphera Pharmaceuticals, LLC's 2015 Equity Incentive Plan. The option vests in 48 equal monthly installments at the end of each month following the vesting commencement date of September 27, 2016, subject to continued service through such dates. Read SEC document |
| December 20, 2016 Filed Dec 23, 2016 19:05 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 6,250 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001662252-16-000301 · form4.xml · derivative · entry 4 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 6,250 shares Expires 2026-11-21 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.49. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
| December 20, 2016 Filed Dec 23, 2016 19:05 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 6,250 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001662252-16-000301 · form4.xml · derivative · entry 3 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires 2026-11-21 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.49. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
| December 20, 2016 Filed Dec 23, 2016 19:05 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 6,250 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001662252-16-000301 · form4.xml · derivative · entry 2 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires 2026-11-21 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.49. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
| December 20, 2016 Filed Dec 23, 2016 19:05 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Option · Derivative | 6,250 | $0.00 Strike: $3.49 | $0.00 |
DisclosureSEC source: 0001662252-16-000301 · form4.xml · derivative · entry 1 Benz Edward J. JR · CIK 0001691160 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires 2026-11-21 F1 · price: On December 20, 2016 the Issuer approved the issuance of a Stock Option Grant to the Reporting Owner under its 2014 Equity Incentive Plan (the "Plan"). The Reporting Owner has the right to purchase 25,000 shares of common stock of the Issuer under the Plan at an exercise price based on the closing price on December 19, 2016 of $3.49. The Option vests one-quarter of the total grant for each quarter of service over the twelve-month period commencing on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.